Short answer
DELCATH SYSTEMS, INC. (DCTH) filed an 8-K current report with the SEC on March 3, 2026 reporting Item 8.01 (Other Events). CHOPIN trial results published in Lancet Oncology, a high-impact peer-reviewed journal: significant clinical validation for Delcath's hepatic delivery platform.
DELCATH SYSTEMS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- CHOPIN trial results published in Lancet Oncology, a high-impact peer-reviewed journal: significant clinical validation for Delcath's hepatic delivery platform
- Publication in Lancet Oncology typically boosts commercial credibility with oncologists and supports broader adoption of HEPZATO KIT
- Full data details in Exhibit 99.1 press release: investors should review for efficacy/safety endpoints that could drive prescriber uptake
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other DELCATH SYSTEMS, INC. 8-K filings
Get the next DCTH 8-K as it lands
Follow DCTH for push alerts, or ask the research agent what this filing means.